GLP-1 Membership Fees Explained (2026)
Many GLP-1 programs split cost into a membership fee plus medication. We explain how to find the true total.
Brand GLP-1 prices collapsed in late 2025 and most comparison pages have not caught up. As of July 12, 2026, brand Zepbound is $299–$449/month through LillyDirect, brand Wegovy is $349 through NovoCare (the oral Wegovy tablet is $149), and either drops to about $25 with commercial coverage that includes it. Retail list prices are $1,086 (Zepbound) and $1,349 (Wegovy). Compounded programs advertise $99–$299 — but they are not FDA-approved and their legal basis narrowed sharply in 2025. All brand figures here are verified against manufacturer sources.
Cost by pathway
Bars use the low end of each pathway's range. Compounded and all-inclusive cash options sit far below retail brand pricing — the tradeoff is FDA-approval status.
| Pathway | Typical cost | Notes | Status |
|---|---|---|---|
| Wegovy tablets (oral semaglutide, brand) | $149/month | NovoCare; 1.5mg & 4mg. 4mg at this price to Aug 31, 2026 | Verified |
| Zepbound 2.5 mg (brand, LillyDirect) | $299/month | Starting dose; no refill-window condition | Verified |
| Wegovy standard (brand, NovoCare) | $349/month | Cut from $499 in Nov 2025. $199 first 2 fills for new patients | Verified |
| Ozempic standard (brand, NovoCare) | $349/month | 0.25-1mg; 2mg is $499 | Verified |
| Zepbound 5 mg (brand, LillyDirect) | $399/month | No refill-window condition | Verified |
| Zepbound 7.5-15 mg (brand, LillyDirect) | $449/month | ONLY if refilled within 45 days of last delivery | Verified |
| Zepbound 10-15 mg — 45-day window missed | $699/month | The penalty rate. A $250/month mistake | Verified |
| Brand + commercial insurance + savings card | as low as $25/month | Zepbound or Wegovy, if your plan covers it | Verified |
| Medicare GLP-1 Bridge (Wegovy) | $50/month | Eligible Part D beneficiaries, Jul 1 2026 - Dec 31 2027 | Verified |
| Retail Zepbound pen (list price) | $1,086/month | What you pay with no program at all | Verified |
| Retail Wegovy (list price) | $1,349/month | What you pay with no program at all | Verified |
| Compounded GLP-1 (telehealth) | $110-$399/month | NOT FDA-approved. Legal basis narrowed sharply in 2025 | Verified |
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
Every fee that can be attached to a GLP-1 programme
An advertised price is a headline. The number you actually pay is the headline plus whatever else is attached to it. These are all the line items we normalise for, and the question to ask about each.
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
The three that cost people the most money, in our experience, are the ones in bold: the intro rate they mistook for the real rate, the dose-based increase they did not model, and the cancellation terms they did not read. None of those are hidden. All of them are simply not asked about.
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Programme A advertises a lower number and costs $1,236 more per year. This is not a hypothetical: the figures are TrimRx's advertised semaglutide rate against NexLife's standard tirzepatide plan. The advertised prices are seven dollars apart. The real prices are over twelve hundred dollars apart.
Brand pricing, verified against the manufacturers
These are the numbers we can stand behind, because they come from Lilly's and Novo's own pricing pages rather than from a comparison site quoting another comparison site.
| Dose | Self-pay price | Condition |
|---|---|---|
| 2.5 mg (starting dose) | $299/mo | No refill-window condition |
| 5 mg | $399/mo | No refill-window condition |
| 7.5 mg | $449/mo | Only if refilled within 45 days — otherwise $499 |
| 10 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 12.5 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 15 mg (maintenance) | $449/mo | Only if refilled within 45 days — otherwise $699 |
| Dose | Price inside window | Price outside window | Penalty |
|---|---|---|---|
| 7.5 mg | $449 | $499 | +$50 |
| 10 mg | $449 | $699 | +$250 |
| 12.5 mg | $449 | $699 | +$250 |
| 15 mg | $449 | $699 | +$250 |
Prices at 7.5 mg and above hold only if you refill within 45 days of the previous delivery. Outside that window the same doses cost $499-$699.
| Product / dose | Self-pay price | Notes |
|---|---|---|
| 0.25 mg / 0.5 mg (first 2 fills, new patients) | $199/mo | Introductory offer through Dec 31, 2026 |
| 0.25–2.4 mg (standard, after intro) | $349/mo | Cut from $499 in November 2025 |
| Wegovy HD 7.2 mg | $399/mo | |
| Wegovy tablets 1.5 mg / 4 mg (oral) | $149/mo | 4 mg at this price through Aug 31, 2026, then $199 |
The finding that changes the decision
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.
How we normalize total cost
Advertised starter prices are not comparable on their own. We calculate a normalized monthly cost that adds required membership, consultation, laboratory, shipping and administrative fees, divided by covered months, and we compute it separately for the initial month, ongoing month, and 3-, 6- and 12-month totals. See the full price-verification methodology.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Why is compounded tirzepatide so much cheaper than Zepbound?
Compounded preparations skip brand manufacturing, packaging and FDA-approval overhead. They are also not FDA-approved and are not quality-verified by the agency before marketing — a real tradeoff, not a free discount.
Can I get GLP-1 medication without insurance?
Yes — cash-pay telehealth and manufacturer direct-pay vial programs exist. Whether compounded options are lawfully available depends on current FDA compounding rules, which have tightened.
What is the cheapest legitimate option?
The lowest advertised starter price in our set is $133/month, but the lowest verified all-inclusive cost after fees was NexLife at $147/month. See our cheapest tirzepatide guide.
Sources
- Eli Lilly — LillyDirect Zepbound pricing page and Zepbound Self Pay Journey Program terms (CMAT-05333, 05/2026), captured July 12, 2026.
- Eli Lilly — press release, "Lilly lowers the price of Zepbound single-dose vials," December 1, 2025.
- Novo Nordisk — NovoCare Pharmacy pricing pages and Wegovy Price Guide, captured July 12, 2026.
- Novo Nordisk — press release, introductory self-pay offer for Wegovy and Ozempic, November 17, 2025.
- U.S. Food and Drug Administration — compounding status and enforcement history.
- Our normalization methodology.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded tirzepatide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.